Amarin Corporation plc
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AMRN research report →
Range $1.5 – $3
Price Chart
About the company
Amarin Corporation plc is a pharmaceutical firm dedicated to the research, development, and commercialization of therapeutic solutions for cardiovascular diseases. Its operations span several international regions, including the United States, Germany, Canada, Lebanon, and the United Arab Emirates. The company's flagship product is VASCEPA, an omega-3 fatty acid formulation available by prescription only.
- CEO
- Aaron D. Berg
- IPO
- 1993
- Employees
- 80
- HQ
- Dublin, DU, IE
Get TickerSpark's AI analysis on AMRN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $222.83M
- P/E
- -0.54
- Fwd P/E
- 55.63
- PEG
- -0.00
- P/S
- 1.35
- P/B
- 0.03
- EV/EBITDA
- -4.94
- Div Yield
- 0.00%
- Gross Margin
- 40.54%
- Op Margin
- -13.97%
- Net Margin
- -10.87%
- ROE
- -4.26%
- ROIC
- -5.33%
Latest fiscal year · YoY change
- Revenue
- $213.65M-6.5%
- Gross Profit
- $120.87M+48.5%
- Op Income
- $-13,941,000
- Net Income
- $-38,798,000+52.8%
- EPS
- $-36.00+55.0%
- OCF Growth
- +121.7%
- FCF Growth
- +121.7%
- 52W High
- $17.31
- 52W Low
- $10.53
- 50D MA
- $12.31
- 200D MA
- $14.06
- Beta
- 0.79
- RSI (14)
- 35
- Avg Volume
- 77.29K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Amarin returned to profitability in Q3 as cost cuts, lower inventory, and stronger international demand offset U.S. pricing pressure.· October 28, 2026
- Reported first profitable quarter in two years, with positive operating cash flow for the quarter and year-to-date.
- International in-market demand accelerated: Europe up an estimated 68% year over year and global partner-network demand up an estimated 55%.
- U.S. branded VASCEPA volume was stable, but revenue fell because of pricing pressure tied to generic competition.
- Cash and investments rose to $324 million, and the company remained debt-free.
- Management highlighted EMT2 colorectal cancer data as an additional scientific opportunity, but said it is still evaluating the path forward.
Total net revenue in Q3 2026 was $39.6 million, versus $49.7 million in Q3 2025. Total product revenue was $36.9 million, versus $48.6 million, and licensing and royalty revenue was $2.7 million, up from $1.1 million. U.S. product revenue was $28.5 million, versus $40.9 million, while Europe product revenue was $3.7 million, versus $4.1 million, and Rest of World product revenue was $4.7 million, versus $3.6 million. Cost of goods sold was $23.4 million, down from $27.5 million, and gross margin improved sequentially by about 2.3 percentage points excluding write-offs. Net income was $245,000, or less than $0.01 per share, compared with a net loss of $7.7 million, or $0.02 per share, a year ago. Operating cash flow was $9 million in the quarter and $22 million for the first nine months, versus a $9 million outflow in the prior-year period. Cash and investments were $324 million, up $21 million from year-end 2025, and the company remained debt-free. Management said it continues to expect positive operating cash flow for the full year. For the U.S., management expects exclusivity to be maintained through the end of 2026 and volumes to remain stable through year-end; pricing is expected to remain relatively consistent through 2026, with continued pricing pressure anticipated into 2027. On Europe and global partnerships, management pointed to continued growth in in-market demand and said launches are being prepared for Singapore and South Korea in early 2027.
Aaron Berg emphasized that the business transformation is producing tangible operational and financial benefits, citing profitable Q3 results, lower expenses, stronger cash generation, and a debt-free balance sheet. He said the company is focused on sustaining positive cash flow, supporting partner growth, and building long-term shareholder value, while remaining disciplined on future capital deployment. His tone was constructive and optimistic, but he repeatedly stressed selectivity and discipline around new opportunities, including the potential broader use of VASCEPA after EMT2.
Pete Fishman framed Q3 as the company’s first profitable quarter in two years, attributing the improvement to restructuring and the company-managed U.S./partnered international model. He pointed to 44% lower operating expenses year over year, a 27% decline in SG&A, no restructuring expense in the quarter versus $9.4 million last year, and a 31% inventory decline from Q4 2024. He also said renegotiated supply contracts helped drive a sequential gross margin improvement of about 2.3 percentage points excluding write-offs, while noting pricing pressure could keep gross margin variable quarter to quarter.
Analysts focused on the disconnect between stable U.S. branded VASCEPA volume and the revenue decline; management said volume was relatively flat and the drop was driven by pricing pressure. On pricing, Pete Fishman said U.S. pricing should remain relatively consistent through year-end because exclusivity is expected to hold, but he added that continued pricing pressure is likely into 2027. Another question centered on European reimbursement and coverage progress and on whether Amarin would seek a partner for any future non-cardiovascular applications; Berg said Recordati is progressing across a broad 59-country footprint and that Amarin will evaluate any new indication based on commercial opportunity, unmet need, existing data, and protection strategy before deciding whether to partner or proceed.
The quarter showed that Amarin can now generate profit and cash even with lower revenue, helped by a meaningfully lower cost base and disciplined working capital management. International demand trends were strong, with Europe up 68% and global partner-network demand up 55%, and management sees further room for growth as more markets launch and reimbursement expands.
U.S. revenue remains pressured by generic competition and lower net selling prices, and management said that pressure is likely to continue into 2027. International revenue can swing with partner inventory and ordering patterns, so reported revenue may not track underlying demand evenly from quarter to quarter. The EMT2 cancer data is interesting but still early, and management emphasized that more analysis is needed before deciding whether it becomes a real development opportunity.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 46.1%
- Shares Outstanding
- 2.10M
- Float Shares
- 968.14K
of shares held by institutions
87 13F filers
Buy/sell ratio 2.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Sarissa Capital Management LP | 1.67M | 0 |
| Acadian Asset Management LLC | 732.95K | ▲ 11.97K |
| Kynam Capital Management, LP | 532.98K | ▲ 60.60K |
| Brooklands Fund Management Ltd | 218.37K | ▲ 41.05K |
| Waterfront Wealth Inc. | 213.71K | ▼ 242 |
| Morgan Stanley | 188.62K | ▼ 35.00K |
| Eversept Partners, LP | 145.30K | ▼ 2.42K |
| Millennium Management LLC | 115.81K | ▼ 184.73K |
| Two Sigma Investments, LP | 100.51K | ▼ 7.03K |
| Citadel Advisors LLC | 95.36K | ▲ 14.79K |
| Bnp Paribas Financial Markets | 69.77K | ▼ 2.04K |
| R Squared Ltd | 49.27K | ▲ 32.33K |
Held by 5 ETFs
Biggest fund positions in AMRN by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 1, 26 | Fishman Peter L. | other | 313 |
| Aug 1, 26 | Fishman Peter L. | other | 155 |
| Aug 1, 26 | Fishman Peter L. | other | 313 |
| Jul 1, 26 | Fishman Peter L. | other | 2,447 |
| Jul 1, 26 | Fishman Peter L. | other | 1,206 |
| Jul 1, 26 | Fishman Peter L. | other | 2,447 |
| Jul 1, 26 | Keenan David Paul | other | 3,688 |
| Jul 1, 26 | Keenan David Paul | other | 1,926 |
| Jul 1, 26 | Keenan David Paul | other | 3,688 |
| Jul 1, 26 | Ketchum Steven B | other | 3,688 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our AMRN coverage
Recent articles, reports, and earnings notes.
No research on AMRN yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate AMRN report →Amarin: 3 Key Takeaways for Long-Term Investors
fool.com · Nov 11
Amarin Highlights New Data on Lipoprotein(a) and other Apolipoprotein B Containing Lipoproteins at American Heart Association (AHA) Scientific Sessions 2026
globenewswire.com · Nov 9
Amarin's Q3 Earnings Beat Estimates, Revenues Miss Mark
zacks.com · Oct 29
Amarin Corporation plc (AMRN) Q3 2026 Earnings Call Transcript
seekingalpha.com · Oct 28
What Amarin (AMRN) Said on Its Q3 Earnings Call
marketbeat.com · Oct 28
Amarin Reports 2026 Third Quarter Financial Results, Achieves Positive Net Income
globenewswire.com · Oct 28
Amarin Provides Update on University of Leeds Sponsored Phase 3 EPA for Metastasis Trial 2 (EMT2) Evaluating VAZKEPA®/VASCEPA® (icosapent ethyl) Capsules on Top of Standard of Care Treatment in Patients Undergoing Liver Resection for Colorectal Cancer Liver Metastases (CRCLM)
globenewswire.com · Oct 25
Amarin to Report Third Quarter 2026 Financial Results and Host Conference Call on October 28, 2026
globenewswire.com · Oct 21
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.